scholarly journals 393 Long-term neurological side effects in long-term survivors with ovarian cancer

2020 ◽  
Author(s):  
N El Ouardi ◽  
H Woopen ◽  
P Huehnchen ◽  
W Boehmerle ◽  
C Leithner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Side Effects ◽  
Long Term Survivors

Fatigue in long-term survivors with ovarian cancer: Results of Expression VI – Carolin meets HANNA – Holistic analysis of Long-term survival with ovarian cancer—The international NOGGO, ENGOT and GCIG survey.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 12065-12065
Author(s):  
Hannah Woopen ◽  
Maren Keller ◽  
Elena Ioana Braicu ◽  
Dario Zocholl ◽  
Petra Krabisch ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Health Status ◽  
Side Effects ◽  
Cognitive Disorders ◽  
Current Treatment ◽  
Term Survival ◽  
Long Term Survival ◽  
The Impact ◽  
Long Term Survivors

12065 Background: Long-term survivors (LTS) with ovarian cancer may be cured from cancer but frequently experience long-term toxicities such as fatigue with a huge impact on quality of life. Aim of this study was to evaluate factors associated with fatigue in LTS. Methods: Within the study “Carolin meets HANNA” ( www.carolinmeetshanna.com ) long-term survivors with ovarian cancer (LTS) were recruited since 11/2016. Long-term survival was defined as an ovarian cancer diagnosis more than eight years ago. Results: Until 12/2019 473 LTS could be recruited. 211 LTS (44.5%) have experienced fatigue. At the time point of recruitment in 23.4% (111 LTS) fatigue was still present. LTS with fatigue were not more frequently under current treatment compared to LTS without fatigue (p = 0.348). LTS with fatigue were not younger at initial diagnosis (50.4 vs. 51.9 years, p = 0.228). 58.6% of LTS with fatigue compared to 41.5% without fatigue have developed recurrent disease (p = 0.002) and LTS had more frequently more than one recurrence (66.1% vs. 51.7%, p = 0.055). Fatigue was associated with worse health status (2.9 vs. 2.2 on a scale from 1-5, p < 0.001). Fatigue was associated with medical complaints in general (82.0% vs. 43.0%, p < 0.001). Symptoms such as nausea and vomiting (p < 0.001), loss of appetite (p < 0.001), constipation (p < 0.001), diarrhea (p < 0.001), weight loss (p = 0.001) and bloating (p < 0.001) were more frequent in LTS with fatigue. This also accounts for cognitive disorders (39.6% vs. 10.5%, p < 0.001), depression (23.4% vs. 7.4%, p < 0.001), polyneuropathy (39.6% vs. 13.2%, p < 0.001) and cardiovascular disease (11.7% vs. 3.6%, p = 0.002). LTS with fatigue regard themselves more frequently as cancer patient (73.9% vs. 40.8%), p < 0.001). Conclusions: Fatigue is still very common in LTS despite the long survival time. Fatigue is associated with worsened health status and other long-term side effects underlining the impact on LTS. There is a high need for survivorship clinics that should ask for and, if necessary, should address still existing side effects such as fatigue.

Health concerns in long-term survivors with ovarian cancer: Results of Expression VI–Carolin meets HANNA–Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCIG survey.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12023-12023
Author(s):  
Hannah Woopen ◽  
Maren Keller ◽  
Ioana Braicu ◽  
Dario Zocholl ◽  
Joanna Baum ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Health Status ◽  
Side Effects ◽  
Survival Time ◽  
Term Survival ◽  
Health Concerns ◽  
Follow Up Care ◽  
Long Term Survivors

12023 Background: So-called long-term survivors (LTS) may be cured from cancer but still experience a wide range of long-term side effects. Aim was to analyze the main concerns in long-term survival to improve follow-up care. Methods: Within the study “Carolin meets HANNA” (www.carolinmeetshanna.com) long-term survivors with ovarian cancer (LTS) were recruited since 11/2016. Long-term survival was defined as an ovarian cancer diagnosis more than five years ago. Results: Until 02/2021 1,044 long-term survivors with ovarian cancer could be recruited. Median survival time at recruitment was 11 years (range 5-43 years). More than half had been diagnosed with advanced stage ovarian cancer (58.6% FIGO III/IV). Almost half have developed recurrent disease (43.4%). 26.0% were under cancer treatment at recruitment. Health status was rated very good or good by 52.0% while 20.3% report a bad or very bad health status. Almost half of the LTS have current concerns/long-term side effects (46.1%). Main concerns are fatigue (23.9%), pain (21.6%), polyneuropathy (16.9%), gastrointestinal symptoms (16.6%) and memory problems (15.5%). 42.8% still regard themselves as cancer patients. Health status and distress did not differ between LTS 5-10 years after diagnosis and > 10 years after diagnosis (p = 0.59 and p = 0.0843 respectively). Patients with a history of recurrence and those under current treatment had a worse health status and more health concerns. LTS without recurrence reported fatigue in 18.4%, pain in 19.2%, polyneuropathy in 13.1%, gastrointestinal problems in 13.4% and memory problems in 14.4%. Fatigue, polyneuropathy, nausea and concentration problems improve with the time of survival. However, fatigue is still present in 21.1% after ten years survival time. There was no significant difference in pain between 5-10 (20.1%) and > 10 years (22.0%) survival time. In this cohort 94.2% receive regular follow-up care including CA125 testing in 77.0%, clinical examination in 54.3%, transvaginal ultrasound in 55.1%, abdominal ultrasound in 43.9%, mammogram in 50.5% and further radiological examinations such as CT scans in 53.4%. Conclusions: Follow-up care in ovarian cancer is usually delivered within the first five years after diagnosis. However, our analyses show the high frequency of health concerns in LTS despite the high frequency of follow-up care in this cohort. Therefore, specialized survivorship care should be offered beyond the typical five years of follow-up care with a focus on long-term side effects.

scholarly journals Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach

2017 ◽  
Vol 146 (1) ◽  
pp. 101-108 ◽  
Author(s):  
Susan K. Lutgendorf ◽  
Eileen Shinn ◽  
Jeanne Carter ◽  
Susan Leighton ◽  
Keith Baggerly ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Advanced Stage ◽  
Cross Sectional ◽  
Long Term Survivors

Salvage radiation therapy for localized recurrent ovarian cancer

2019 ◽  
Vol 29 (5) ◽  
pp. 916-921
Author(s):  
Alicia Smart ◽  
Yu-Hui Chen ◽  
Teresa Cheng ◽  
Martin King ◽  
Larissa Lee
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Clear Cell ◽  
Recurrent Ovarian Cancer ◽  
Salvage Radiotherapy ◽  
Platinum Sensitive ◽  
Long Term Survivors ◽  
Disease Free

IntroductionTo evaluate clinical outcomes for patients with localized recurrent ovarian cancer treated with salvage radiotherapy.MethodsIn a retrospective single institutional analysis, we identified 40 patients who received salvage radiotherapy for localized ovarian cancer recurrence from January 1995 to June 2011. Recurrent disease was categorized as: pelvic peritoneal (45%, 18), extraperitoneal/nodal (35%, 14), or vaginal (20%, eight). Actuarial disease-free and overall survival estimates were calculated by Kaplan–Meier and prognostic factors evaluated by the Cox proportional hazards model.ResultsMedian follow-up was 42 months. Median patient age was 54 years (range, 27–78). Histologic subtypes were: serous (58%, 23), endometrioid (15%, six), clear cell (13%, five), mucinous (8%, three), and other (8%, three). At the time of salvage radiotherapy, surgical cytoreduction was performed in 60% (24) and 68% (27) had platinum-sensitive disease. Most patients (63%, 25) received salvage radiotherapy at the time of first recurrence. Relapse after salvage radiotherapy occurred in 29 patients at a median time of 16 months and was outside the radiotherapy field in 62%. 18 At 3 years, disease-free and overall survival rates were 18% and 80%, respectively. On multivariate analysis, non-serous histology (hazards ratio 0.3, 95% CI 0.1–0.7) and platinum-sensitivity (hazards ratio 0.2, 95% CI 0.1–0.5) were associated with lower relapse risk. Platinum-sensitivity was also associated with overall survival (hazards ratio 0.4, 95% CI 0.1–1.0). Four patients (10%) were long-term survivors without recurrence 5 years after salvage radiotherapy. Of the five patients with clear cell histology, none experienced relapse at the time of last follow-up.DiscussionPatients with non-serous and/or platinum-sensitive ovarian cancer had the greatest benefit from salvage radiotherapy for localized recurrent disease. Although relapse was common, radiotherapy prolonged recurrence for > 1 year in most patients and four were long-term survivors.

Abstract 2722: The genomic landscape of high-grade serous ovarian cancer in long-term survivors

2019 ◽  
Author(s):  
Dale W. Garsed ◽  
Ahwan Pandey ◽  
Sian Fereday ◽  
Kathryn Alsop ◽  
Maartje C. Wouters ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Genomic Landscape ◽  
Long Term Survivors

Conditional probability of survival (CPS) in ovarian cancer (OC) long-term survivors: Prognostic factors.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16514-e16514
Author(s):  
Michel Fabbro ◽  
Pierre Emmanuel Colombo ◽  
Caroline Mollevi ◽  
Julie Bensakkoun ◽  
Isabelle Coupier
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Conditional Probability ◽  
Probability Of Survival ◽  
Long Term Survivors

Implications of high expression of miR17-92 cluster in ovarian cancer (OvCa) tissue found in long term survivors.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12561-e12561
Author(s):  
Devika Prasanna ◽  
Ahmad Bassam Shaker ◽  
Alejandro Recio Boiles ◽  
Michaela Oswald ◽  
Cathleen Mason ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Expression ◽  
Long Term Survivors

scholarly journals Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention

2014 ◽  
Vol 87 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Melinda Csapo ◽  
Liviu Lazar
Keyword(s):  
Side Effects ◽  
Adverse Reactions ◽  
Cardiac Toxicity ◽  
Negative Impact ◽  
Therapeutic Strategies ◽  
Oncological Treatment ◽  
Cardiac Side Effects ◽  
Long Term Survivors ◽  
Remarkable Progress

Along with the remarkable progress registered in oncological treatment  that led to increased survival of cancer patients, treatment-related comorbidities have also become an issue for these long-term survivors. Of particular interest is the development of cardiotoxic events, which, even when asymptomatic, not only have a negative impact on the patient`s cardiac prognosis, but also considerably restrict therapeutic opportunities. The pathophysiology of cytostatic-induced cardiotoxicity implies a series of complex and intricate mechanisms, whose understanding enables the development of preventive and therapeutic strategies. Securing cardiac function is an ongoing challenge for the pharmaceutical industry and the physicians who have to deal currently with these adverse reactions. This review focuses on the main mechanism of cardiac toxicity induced by anticancer drugs and especially on the current strategies applied for preventing and minimizing the cardiac side effects.

scholarly journals “Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
François Gernier ◽  
Djihane Ahmed-Lecheheb ◽  
Patricia Pautier ◽  
Anne Floquet ◽  
Cédric Nadeau ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Side Effects ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Chronic Fatigue ◽  
Stromal Tumors ◽  
Sex Cord Stromal Tumors

Abstract Background Germ cell tumors and sex cord stromal tumors are rare cancers of the ovary. They mainly affect young women and are associated with a high survival rate. The standard treatment mainly involves conservative surgery combined with chemotherapy [bleomycin, etoposide and cisplatin (BEP)] depending on the stage and the prognostic factors, as for testicular cancers. As reported in testicular cancer survivors, chemotherapy may induce sequelae impacting quality of life, which has not yet been evaluated in survivors of germ cell tumors and sex cord stromal tumors. The GINECO-VIVROVAIRE-Rare tumor study is a two-step investigation aiming to assess i) chronic fatigue and quality of life and ii) long-term side-effects of chemotherapy with a focus on cardiovascular and pulmonary disorders. Methods Using self-reported questionnaires, chronic fatigue and quality of life are compared between 134 ovarian cancer survivors (cancer-free ≥2 years after treatment) treated with surgery and chemotherapy and 2 control groups (67 ovarian cancer survivors treated with surgery alone and 67 age-matched healthy women). Medical data are collected from patient records. In the second step evaluating the long-term side-effects of chemotherapy, a subgroup of 90 patients treated with chemotherapy and 45 controls undergo the following work-up: cardiovascular evaluation (clinical examination, non-invasive cardiovascular tests to explore heart disease, blood tests), pulmonary function testing, audiogram, metabolic and hormonal blood tests. Costs of sequelae will be also assessed. Patients are selected from the registry of the INCa French Network for Rare Malignant Ovarian Tumors, and healthy women by the ‘Seintinelles’ connected network (collaborative research platform). Discussion This study will provide important data on the potential long-term physical side-effects of chemotherapy in survivors of Germ Cell Tumors (GCT) and Sex Cord Stromal Tumors (SCST), especially cardiovascular and pulmonary disorders, and neurotoxicity. The identification of long-term side-effects can contribute to adjusting the treatment of ovarian GCT or SCST patients and to managing follow-up with adapted recommendations regarding practices and chemotherapy regimens, in order to reduce toxicity while maintaining efficacy. Based on the results, intervention strategies could be proposed to improve the management of these patients during their treatment and in the long term. Trial registration This trial was registered at clinicaltrials.gov: 03418844, on 1 February 2018. This trial was registered on 25 October 2017 under the unique European identification number (ID-RCB): 2017-A03028–45. Recruitment Status: Recruiting. Protocol version Version n° 4.2 dated from Feb 19, 2021. Trial sponsor Centre François Baclesse, 3 avenue du Général Harris, F-14076 Caen cedex 05, France.

Sign in / Sign up

Export Citation Format

Share Document